Abstract: This invention relates to an IgG-binding peptide, an IgG-binding peptide modified with a cross-linking agent, a conjugate of the IgG-binding peptide modified with a cross-linking agent and IgG, and a method for producing the conjugate, etc.

Abstract: The present invention relates to an agent for killing HIV-1-infected cells, comprising a compound represented by formula (I): wherein Ar1 and Ar2 are the same or different and represent a substituted or unsubstituted aromatic group, and X represents —CH2O— or —CH?CH—, its salt, or their solvate, and a combined preparation for simultaneous, separate, or sequential administration in treating or preventing HIV-1 infection, comprising two separate preparations: (a) a preparation comprising a compound represented by the formula (I), its salt, or their solvate, and (b) a preparation comprising an anti-HIV-1 drug.

Abstract: An observation and photography apparatus that has a polishing mechanism attached thereto. The polishing mechanism is provided with a turntable with a perpendicular rotation shaft, a polishing cloth for polishing the surface of a sample attached to the bottom surface of the turntable, and a polishing-fluid spraying nozzle disposed below the polishing cloth for spraying polishing fluid containing polishing material upward to we the polishing cloth.

Abstract: Provided is a pain-related compound, a pain-related pharmaceutical composition, and use of the same. Provided in one or more embodiments is a compound represented by Formula (I), a prodrug of the same, or a pharmaceutically permissible salt of any of the same.

Abstract: According to this invention, the following are provided: a pharmaceutical composition for treating and/or preventing esophageal stenosis, comprising an HGF protein as an active ingredient (wherein the HGF protein may be a polypeptide that is any one of the following: (a) a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 2; (b) a polypeptide comprising an amino acid sequence shown in SEQ ID NO: 2 in which one to several amino acids are deleted, substituted, or added; or (c) a polypeptide comprising an amino acid sequence having at least 90% identity with the amino acid sequence shown in SEQ ID NO: 2; and a stent comprising the pharmaceutical composition.

Abstract: Techniques are provided in which a “dichromat” (e.g., a color-blind person) is able to identify the hue of an object without determining the color difference signals that are applied to the original color image. Such features may be implemented by performing hue rotation processing on each pixel data of the original color image captured.

Abstract: A high-density shape reconstruction is conducted in measuring animal bodies as well. An image processing system has a projection device, an imaging device, and an image processing apparatus connected to the projection device and the imaging device, wherein the projection device projects a projected pattern to an observation target, the imaging device captures the projected pattern, and the image processing apparatus performs shape reconstruction based on an input image including the projected pattern. The image processing apparatus includes a unit for fetching the input image captured by the imaging device and performing line detection for the projected pattern projected by the projection device, wherein the projected pattern is a grid pattern formed of wave lines; and a unit for performing shape reconstruction by associating intersection points of vertical and horizontal lines extracted by the line detection with the projected pattern.

Abstract: The present invention provides a method for detection of a basic peptide by mixing a sample suspected to contain the basic peptide and a reagent containing denatured albumin and detecting turbidness due to a complex of the basic peptide and denatured albumin.

Abstract: This invention relates to: a peptide which comprises an amino acid sequence consisting of 12 to 18 amino acid residues represented by (X1-3)—C—(X8-10)—C—(X1-3) wherein each X independently represents an arbitrary amino acid residue other than cysteine, and C represents a cysteine residue, and is capable of binding to human IgA; and to a method for analyzing or purifying human IgA using the peptide.

Abstract: The present invention relates to a detection method for a genetic disease, and specifically relates to detection of disease-causing genes for autosomal recessive inherited Charcot-Marie-Tooth disease (CMT). In the method according to the present invention, a mutation(s) in MME (membrane metallo-endopeptidase) gene, FAT3 (FAT tumor suppressor homolog 3) gene, and/or SELRC1 (Sell repeat containing 1) gene in a biological sample are/is detected.

Abstract: Provided is a pain-related compound, a pain-related pharmaceutical composition, and use of the same. Provided in one or more embodiments is a compound represented by Formula (I), a prodrug of the same, or a pharmaceutically permissible salt of any of the same.

Abstract: The object of the present invention is to provide an antibody capable of immunologically and specifically binding to a folate receptor ? and a folate receptor ?. Specifically, the present invention relates to an antibody or a fragment thereof, in which the amino acid sequences of CDRH1, CDRH2, and CDRH3 of a heavy chain variable region (VH) are SEQ ID NOs: 2, 4, and 6, respectively, and the amino acid sequences of CDRL1, CDRL2, and CDRL3 of a light chain variable region (VL) are SEQ ID NOs: 10, 12, and 14, respectively.

Abstract: A method for concentrating viruses includes applying a magnetic force to a mixture containing: sugar chain-immobilized magnetic metal nano-particles each having a structure in which a sugar chain-immobilized metal nano-particle is bound to a first magnetic nano-particle; second magnetic particles with mean particle size larger than that of the sugar chain-immobilized magnetic metal nano-particles; and a specimen. Each sugar chain-immobilized metal nano-particle has a structure where a ligand-conjugate is bound to a metal nano-particle via sulfur atoms. The ligand-conjugate has a structure where a linker compound's amino group is connected to a sugar chain having a reducing terminal. The linker compound includes, in molecules thereof, an amino group, sulfur atoms, and a hydrocarbon chain having carbon-nitrogen bonds.

Abstract: Disclosed is a thermotherapy in which a thermal gas such as hot vapor which is warm vapor is inhaled through a mouth or a nose, and the inhaled thermal gas spreads to every alveolus of lungs. Due to such a thermotherapy, the whole respiratory organ is warmed and, at the same time, heat energy is applied to blood through the alveoli of the lungs so that human body tissues are easily warmed within a short time by transferring the heat energy to whole parts of a human body by making use of the circulation of blood. Accordingly, not only a healthy person but also a patient can easily enjoy advantageous effects of a thermotherapy which is equal to or higher than advantageous effects of a sauna or hot spring.

Abstract: Embodiments of the present invention provide a topical agent that is a preparation containing hydrolyzed silk. The topical agent is applied to a wound site for use in wound healing, an thus, an object thereof being to have an effect of promoting wound healing and to satisfy practical application conditions with regard to an irritative property, stability, handling ease, and the like. The topical agent contains hydrolyzed fibroin, an oil-based component, and a water-based component. The topical agent according to the embodiments of the present invention is preferably an ointment or a cream. The topical agent contains hydrolyzed fibroin as an active ingredient in an amount of 1 to 40 wt %, and preferably does not contain a surfactant.

Abstract: Provided is a peptide that specifically or selectively binds to human IgG. This peptide comprises an amino acid sequence consisting of 13 to 17 amino acid residues and is capable of binding to human IgG, wherein the amino acid sequence is represented by formula I: (X1-3)-C-(X2)-H-R-G-(Xaa1)-L-V-W-C-(X1-3), wherein, X each independently represents any amino acid residue except cysteine, C represents a cysteine residue, H represents a histidine residue, R represents an arginine residue, G represents a glycine residue, Xaa1 represents a glutamic acid residue or an asparagine residue, L represents a leucine residue, V represents a valine residue, and W represents a tryptophan residue.

Abstract: The present invention relates to antibodies which bind human ghrelin and their use in methods of treating or preventing reduced appetite. The invention further relates to diagnostic tools for determining whether an individual is likely to respond to a method of treating or preventing reduced appetite.

Abstract: A training device for training a limb includes target parts to be touched with the limb and a force generator that generates a lifting force acting upward on the limb by electricity in a manner allowing the limb to move upward and downward.

Abstract: A training device is for training a limb. The training device includes switches that are manipulated with the limb and a load reliever that generates a counter force against the weight of the limb in a manner allowing the limb to move upward and downward.

Abstract: This invention relates to a pharmaceutical composition for inhibiting the growth and/or metastasis of invasive pancreatic cancer in a subject, comprising a molecular-targeted anticancer agent and a pharmaceutically acceptable carrier, wherein the molecular-targeted anticancer agent is a conjugate of a toxin or cytotoxic agent and an antibody or fragment thereof which immunologically and specifically binds to a cell-surface folate receptor ? (FR?) protein of an FR? (+) macrophage that exists around pancreatic cancer cells at the invasive front, and to a diagnostic agent and kit for determining the degree of malignancy of pancreatic cancer or the presence of invasive pancreatic cancer, characterized by determining that the cancer tissue is invasive and metastatic when FR? (+) macrophage is distributed around pancreatic cancer cells at the invasive front.